Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Iteos Therapeutics Inc (ITOS)

Iteos Therapeutics Inc (ITOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 568,215
  • Shares Outstanding, K 36,123
  • Annual Sales, $ 12,600 K
  • Annual Income, $ -112,640 K
  • 60-Month Beta 1.40
  • Price/Sales 46.75
  • Price/Cash Flow N/A
  • Price/Book 1.08
Trade ITOS with:

Options Overview Details

View History
  • Implied Volatility 130.14% ( -8.67%)
  • Historical Volatility 49.33%
  • IV Percentile 93%
  • IV Rank 76.25%
  • IV High 159.53% on 03/01/24
  • IV Low 35.77% on 12/12/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 541
  • Put/Call OI Ratio 4.54
  • Today's Open Interest 24,578
  • Open Int (30-Day) 21,302

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.04
  • Number of Estimates 4
  • High Estimate -0.80
  • Low Estimate -1.15
  • Prior Year -0.96
  • Growth Rate Est. (year over year) -8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.06 +22.43%
on 07/05/24
17.71 -9.71%
on 07/16/24
+1.19 (+8.04%)
since 06/21/24
3-Month
10.26 +55.85%
on 04/25/24
18.75 -14.72%
on 05/10/24
+5.20 (+48.19%)
since 04/22/24
52-Week
8.20 +95.00%
on 10/12/23
18.75 -14.72%
on 05/10/24
+1.41 (+9.67%)
since 07/21/23

Most Recent Stories

More News
NCR Atleos Set to Join S&P SmallCap 600

/PRNewswire/ -- NCR Atleos Corp. (NYSE: NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of...

SPGI : 484.67 (+1.01%)
ITOS : 15.87 (+0.89%)
NATL : 33.95 (+0.06%)
NCR : 27.08 (+3.24%)
VYX : 14.59 (-0.34%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – June 8, 2023 – USA News Group  –  By utilizing newly developed novel mechanisms, biotech researchers and scientists are...

ONCY : 1.0250 (-0.49%)
ONC.TO : 1.41 (unch)
GILD : 72.20 (-0.50%)
ITOS : 15.87 (+0.89%)
GSK : 39.38 (+0.08%)
PGEN : 1.5950 (+0.31%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

/PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against...

ONC.TO : 1.41 (unch)
ONCY : 1.0250 (-0.49%)
GILD : 72.20 (-0.50%)
ITOS : 15.87 (+0.89%)
GSK : 39.38 (+0.08%)
PGEN : 1.5950 (+0.31%)
Novel Mechanisms Leading the Charge in Fight Against Cancer, Opening Door to New Drugs & Therapies

USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of...

ONCY : 1.0250 (-0.49%)
ONC.TO : 1.41 (unch)
GILD : 72.20 (-0.50%)
ITOS : 15.87 (+0.89%)
GSK : 39.38 (+0.08%)
PGEN : 1.5950 (+0.31%)
iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update

- Began enrolling patients with head and neck squamous cell carcinoma in Phase 2 trial expansion evaluating anti-TIGIT monoclonal antibody,...

ITOS : 15.87 (+0.89%)
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical...

ITOS : 15.87 (+0.89%)
Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced...

ITOS : 15.87 (+0.89%)
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update

Enrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with...

ITOS : 15.87 (+0.89%)
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022

Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients...

ITOS : 15.87 (+0.89%)
iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

- Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab-gxly) and EOS-448 combination trial...

ITOS : 15.87 (+0.89%)

Business Summary

iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery and development of immuno-oncology therapeutics. iTeos Therapeutics Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 17.29
2nd Resistance Point 16.91
1st Resistance Point 16.32
Last Price 15.87
1st Support Level 15.35
2nd Support Level 14.97
3rd Support Level 14.38

See More

52-Week High 18.75
Last Price 15.87
Fibonacci 61.8% 14.72
Fibonacci 50% 13.48
Fibonacci 38.2% 12.23
52-Week Low 8.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar